<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289352</url>
  </required_header>
  <id_info>
    <org_study_id>71304906</org_study_id>
    <nct_id>NCT02289352</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea</brief_title>
  <official_title>A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (Brimonidine) Topical Gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients With Moderate to Severe Facial Erythema Associated With Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Watson Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to&#xD;
      Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson&#xD;
      Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33%&#xD;
      (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema&#xD;
      Associated with Rosacea&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 462 patients 18 years of age and older, with confirmed clinical diagnosis of rosacea&#xD;
      will be enrolled to have 413 in the modified intent-to-treat (mITT) population and 371 in the&#xD;
      per-protocol (PP) population. Patients should have fewer than 3 facial inflammatory lesions,&#xD;
      and moderate to severe erythema according to both Clinician's Erythema Assessment (CEA) and&#xD;
      Patient's Self-Assessment (PSA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary: Percentage of Treatment Success on Day 7</measure>
    <time_frame>7 days</time_frame>
    <description>Percentage of patients with a clinical response of treatment success on Day 7 (± 1). Treatment success is defined as at least a 2-grade improvement on both CEA and PSA scores from baseline (pre-dose) on Day 7 (± 1) to 6 hours post-application on Day 7 (± 1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With a Clinical Response of Treatment Success on Day 1</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">462</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>brimonidine 0.33% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirvaso gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical gel base only (Watson Laboratories Inc., USA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine</intervention_name>
    <arm_group_label>Mirvaso gel</arm_group_label>
    <arm_group_label>brimonidine 0.33% gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant, non-lactating female, 18 years of age or older.&#xD;
&#xD;
          2. Signed informed consent form, which meets all criteria of current FDA regulations.&#xD;
&#xD;
          3. Females of child bearing potential must not be pregnant or lactating at Screening and&#xD;
             Randomization (as confirmed by a negative urine pregnancy test with a sensitivity of&#xD;
             less than 25 mlU/mL or equivalent units of human chorionic gonadotropin). Women of&#xD;
             childbearing potential must agree to the use of a reliable method of contraception&#xD;
             (e.g., total abstinence, IUD, a double-barrier method [such as condom plus diaphragm&#xD;
             with spermicide], oral, transdermal, injected or implanted non- or hormonal&#xD;
             contraceptive), throughout the study. A sterile sexual partner is not considered an&#xD;
             adequate form of birth control.&#xD;
&#xD;
             All females will be considered to be of childbearing potential unless they:&#xD;
&#xD;
               -  Are post-menopausal, defined as women who have been amenorrheic for at least 12&#xD;
                  consecutive months, without other known or suspected primary cause.&#xD;
&#xD;
               -  Have been sterilized surgically or who are otherwise proven sterile (i.e., total&#xD;
                  hysterectomy, or bilateral oophorectomy) with surgery at least 4 weeks prior to&#xD;
                  Screening. Tubal ligation will not be considered a surgically sterile method.&#xD;
&#xD;
             Female patients of childbearing potential are defined as:&#xD;
&#xD;
               -  Women without prior hysterectomy, or who have had any evidence of menses in the&#xD;
                  past 12 months.&#xD;
&#xD;
               -  Females who have been amenorrhea for ≥ 12 months, but the amenorrhea is possibly&#xD;
                  due to other causes, including prior chemotherapy, anti-estrogens, or ovarian&#xD;
                  suppression.&#xD;
&#xD;
          4. Have a clinical diagnosis of facial rosacea and fewer than 3 inflammatory lesions on&#xD;
             the face at Screening and at Randomization (before drug application on Day 1).&#xD;
&#xD;
          5. Have moderate to severe facial erythema according to both CEA and PSA (i.e., an&#xD;
             erythema score of 3 or more for each of the CEA and PSA) at Screening and at&#xD;
             Randomization (before drug application on Day 1).&#xD;
&#xD;
          6. Free from any systemic or dermatologic disorder (other than rosacea) that, in the&#xD;
             opinion of the Investigator, will interfere with the study evaluations or increase the&#xD;
             risk of AEs.&#xD;
&#xD;
          7. Willing to minimize external factors that might trigger rosacea flare-ups (e.g., hot&#xD;
             environments, prolonged sun exposure, strong winds and emotional stress) within 24&#xD;
             hours of the Screening and Randomization visit.&#xD;
&#xD;
          8. Any skin type or race, providing the skin pigmentation will allow discernment of&#xD;
             erythema.&#xD;
&#xD;
          9. Willingness and capability to cooperate to the extent and degree required by the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with particular forms of rosacea (rosacea conglobata, rosacea fulminans,&#xD;
             isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial&#xD;
             dermatoses similar to rosacea, such as peri-oral dermatitis, demodicidosis, facial&#xD;
             keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic&#xD;
             telangiectasia, that are present on the face (i.e., 5 areas: chin, nose, both cheeks,&#xD;
             and forehead), that in the opinion of the Investigator would interfere with study&#xD;
             evaluations.&#xD;
&#xD;
          2. Have 3 or more facial inflammatory lesions of rosacea.&#xD;
&#xD;
          3. Have an erythema score of 2 (mild), 1 (almost clear), or 0 (clear) on the CEA and/or&#xD;
             the PSA at Screening and at Randomization (before drug application on Day 1).&#xD;
&#xD;
          4. Patients with excessive facial hair (beards, sideburns, mustaches, etc.) that would&#xD;
             interfere with the diagnosis or assessment of rosacea.&#xD;
&#xD;
          5. Patients with moderate to severe telangiectasial masses in the 5 areas of the entire&#xD;
             face: forehead, chin, nose and each cheek, that would interfere with study&#xD;
             evaluations.&#xD;
&#xD;
          6. History of hypersensitivity or allergy to Mirvaso® including the active ingredient&#xD;
             brimonidine tartarate or other component within the formulation.&#xD;
&#xD;
          7. Facial laser surgery for telangiectasia (or other conditions) within 6 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
          8. Exposed to excessive ultraviolet (UV) radiation within 1 week before screening or&#xD;
             randomization visit and/or patient was unwilling to refrain from excessive exposure to&#xD;
             UV radiation during the course of the study.&#xD;
&#xD;
          9. History of blood dyscrasia.&#xD;
&#xD;
         10. Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic&#xD;
             hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal&#xD;
             or hepatic impairment, scleroderma, Sjögren's syndrome, or depression, or any other&#xD;
             condition causing uncontrolled blood flow or blood pressure.&#xD;
&#xD;
         11. Females who are pregnant, lactating or likely to become pregnant during the study.&#xD;
&#xD;
         12. Significant history or current evidence of chronic infectious disease, system&#xD;
             disorder, organ disorder or other medical condition that in the Investigator's opinion&#xD;
             would place the study patient at undue risk by participation.&#xD;
&#xD;
         13. Patients with severe, unstable or uncontrolled cardiovascular disease.&#xD;
&#xD;
         14. Patients who meet study restrictions at Screening and Randomization and/or&#xD;
             unwillingness to comply with all restricted treatments&#xD;
&#xD;
         15. Receipt of any drug as part of a research study within 30 days before dosing.&#xD;
&#xD;
         16. Employees of the research center or Investigator.&#xD;
&#xD;
         17. Previous participation in this study.&#xD;
&#xD;
         18. Patients who are unable and/or unwilling to follow the study requirements, and&#xD;
             procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nageshwar R Thudi, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Actavis Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator site 2</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 16</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 5</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 7</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 8</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 6</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 3</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 9</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 14</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 15</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 1</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 10</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 11</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 4</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 13</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 12</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 31, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <results_first_submitted>November 26, 2019</results_first_submitted>
  <results_first_submitted_qc>January 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2020</results_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>514 patients were screened for study participation and 462 patients were randomized and included in the statistical analysis.&#xD;
The populations for this study included the Safety population, the Per-Protocol (PP) population and the modified Intent-to-Treat (mITT) Population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Test: Brimonidine 0.33% Gel</title>
          <description>Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)&#xD;
Participants applies a once-daily application of brimonidine gel (pea-sized amount to each of 5 areas of the entire face for 7 days).</description>
        </group>
        <group group_id="P2">
          <title>Reference: Mirvaso 0.33% Gel</title>
          <description>Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)&#xD;
Participants applies a once-daily application of brimonidine gel (pea-sized amount to each of 5 areas of the entire face for 7 days).</description>
        </group>
        <group group_id="P3">
          <title>Placebo Gel Vehicle</title>
          <description>Topical gel base only (Watson Laboratories Inc., USA)&#xD;
Participants applies a once-daily application of brimonidine gel (pea-sized amount to each of 5 areas of the entire face for 7 days).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="199"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="199"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>mITT Population</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="193"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PP Population</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="173"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="198"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test:Brimonidine 0.33% Gel</title>
          <description>Participants applies a once-daily application of brimonidine gel (pea-sized amount to each of 5 areas of the entire face for 7 days).</description>
        </group>
        <group group_id="B2">
          <title>Reference: Mirvaso 0.33% Gel</title>
          <description>Participants applies a once-daily application of brimonidine gel (pea-sized amount to each of 5 areas of the entire face for 7 days).</description>
        </group>
        <group group_id="B3">
          <title>Placebo Gel Vehicle</title>
          <description>Participants applies a once-daily application of brimonidine gel (pea-sized amount to each of 5 areas of the entire face for 7 days).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="199"/>
            <count group_id="B2" value="199"/>
            <count group_id="B3" value="64"/>
            <count group_id="B4" value="462"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="384"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="360"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="318"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="460"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary: Percentage of Treatment Success on Day 7</title>
        <description>Percentage of patients with a clinical response of treatment success on Day 7 (± 1). Treatment success is defined as at least a 2-grade improvement on both CEA and PSA scores from baseline (pre-dose) on Day 7 (± 1) to 6 hours post-application on Day 7 (± 1).</description>
        <time_frame>7 days</time_frame>
        <population>Participants in the mITT Population that were evaluated for percentage of treatment successes.</population>
        <group_list>
          <group group_id="O1">
            <title>Test: Brimonidine 0.33% Gel</title>
            <description>Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)&#xD;
Test Brimonidine</description>
          </group>
          <group group_id="O2">
            <title>Reference: Mirvaso 0.33% Gel</title>
            <description>Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)&#xD;
Reference Brimonidine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Vehicle gel</description>
          </group>
        </group_list>
        <measure>
          <title>Primary: Percentage of Treatment Success on Day 7</title>
          <description>Percentage of patients with a clinical response of treatment success on Day 7 (± 1). Treatment success is defined as at least a 2-grade improvement on both CEA and PSA scores from baseline (pre-dose) on Day 7 (± 1) to 6 hours post-application on Day 7 (± 1).</description>
          <population>Participants in the mITT Population that were evaluated for percentage of treatment successes.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.95"/>
                    <measurement group_id="O2" value="10.36"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the 90% confidence interval for the absolute difference between the proportion of patients considered a treatment success (at least a 2-grade improvement on both CEA and PSA over 6 hours+/-10 minutes) in the Test and Reference groups is contained within the range [-20%, +20%], then bioequivalence of the Test product to the Reference product is considered to have been demonstrated.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.49</ci_lower_limit>
            <ci_upper_limit>5.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With a Clinical Response of Treatment Success on Day 1</title>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test: Brimonidine 0.33% Gel</title>
            <description>Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)&#xD;
Test Brimonidine</description>
          </group>
          <group group_id="O2">
            <title>Reference: Mirvaso 0.33% Gel</title>
            <description>Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)&#xD;
Reference Brimonidine</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo Vehicle gel</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Clinical Response of Treatment Success on Day 1</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.89"/>
                    <measurement group_id="O2" value="30.89"/>
                    <measurement group_id="O3" value="8.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The secondary efficacy variable is the proportion of patients with a clinical response of treatment success on Day 1.&#xD;
If the 90% confidence interval for the absolute difference between the proportion of patients considered a treatment success (at least a 2-grade improvement on both the CEA and PSA over 6 hours+/-10 minutes) in the Test and Reference groups is contained within the range [-20%, 20%], then bioequivalence of the Test to Reference product is considered to have been demonstrated.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.54</ci_lower_limit>
            <ci_upper_limit>15.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0045</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Day 7</time_frame>
      <desc>Adverse events were collected from participants who were randomized and received the study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Test:Brimonidine 0.33% Gel</title>
          <description>Participants applies a once-daily application of brimonidine gel (pea-sized amount to each of 5 areas of the entire face for 7 days).</description>
        </group>
        <group group_id="E2">
          <title>Reference: Mirvaso 0.33% Gel</title>
          <description>Participants applies a once-daily application of brimonidine gel (pea-sized amount to each of 5 areas of the entire face for 7 days).</description>
        </group>
        <group group_id="E3">
          <title>Placebo Gel Vehicle</title>
          <description>Participants applies a once-daily application of brimonidine gel (pea-sized amount to each of 5 areas of the entire face for 7 days).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Application site papules</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Application site warmth</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart Rate Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, CE Studies</name_or_title>
      <organization>Teva Pharmaceuticals USA, Inc.</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedInfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

